Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 48,479 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: AS+ Clear all

Conditions: Chronic Pelvic Pain, Interstitial Cystitis, Post Traumatic Stress Disorder, Fibromyalgia, Irritable Bowel Syndrome
Interventions: tDCS; Procedure
Lead sponsor: Summa Health System; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Thoracic Fracture, Lumbar Fracture, Compression Fracture of Thoracic Vertebral Body, Compression Fracture of Lumbar Spine, Burst Fracture of Thoracic Vertebra, Burst Fracture of Lumbar Vertebra
Interventions: Spinal Orthosis (LSO, TLSO), No orthosis; Other
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dry Eye Syndromes, Dry Eye
Interventions: RGN-259, Placebo; Drug
Lead sponsor: ReGenTree, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 20
States / cities: Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 16 more

Conditions: Gender Dysphoria
Interventions: Mastectomy and chest masculinization; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 13 Years to 25 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Chicago, Illinois

Conditions: Respiratory Depression
Interventions: ENA-001, Placebo Comparator; Drug
Lead sponsor: Enalare Therapeutics Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Miami, Florida • Overland Park, Kansas

Conditions: Burnout, Professional
Interventions: Control, Resilience coaching; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Carcinoma, Hepatocellular
Interventions: Atezolizumab, Bevacizumab, Sorafenib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 21
States / cities: Phoenix, Arizona • Duarte, California • La Jolla, California + 17 more

Conditions: Acute Respiratory Failure
Interventions: Ketamine, Sedative drug regimen; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Complex Post-Traumatic Stress Disorder, Post-traumatic Stress Disorder
Interventions: Trauma-focused psychodynamic psychotherapy; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Foot Ulcer
Interventions: BR-AC, Standard Care; Other
Lead sponsor: BioStem Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 11
States / cities: San Francisco, California • Sylmar, California • Torrance, California + 8 more

Conditions: Traumatic Brain Injury
Interventions: VR Executive Functions Training, VR Placebo Game; Behavioral
Lead sponsor: University of Massachusetts, Lowell; Other
Eligibility: 7 Years to 17 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Substance Abuse
Interventions: BHCDS-based recommendations, Non-tailored recommendations; Behavioral
Lead sponsor: Inflexxion, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions: Laboratory Biomarker Analysis, Pemetrexed Disodium, Sunitinib Malate; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 129
States / cities: Anaheim, California • Arroyo Grande, California • Baldwin Park, California + 90 more

Conditions: Critically Ill, Post Intensive Care Syndrome
Interventions: Therapeutic Vibration Device; Diagnostic Test
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Asthma
Interventions: None (observational study); Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 8,681 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions: depsipeptide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Bethesda, Maryland + 5 more

Conditions: C-Reactive Protein
Interventions: LY5625573, Midazolam, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Los Alamitos, California • Dallas, Texas

Conditions: Obesity, PreDiabetes, Aging
Interventions: DPP Intensive: 30-minute calls, DPP Support: 15-minute calls; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 314 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pediatric Hypertension
Interventions: Control condition, QIC with PCP and without subspecialist, QIC with Subspecialist, Hub and Spoke co-management, Sustainability of changes; Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions: Vadadustat, Darbepoetin alfa; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 54
States / cities: Huntsville, Alabama • Mesa, Arizona • Anaheim, California + 45 more

Conditions: N/A Healthy Individuals
Interventions: Myofascial Release, Light Touch Contact; Other
Lead sponsor: New York Institute of Technology; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Old Westbury, New York

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01%; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Bakersfield, California • Newport Beach, California • Morrow, Georgia + 1 more

Conditions: Coma, Disorders of Consciousness, Cardiac Arrest (CA), Traumatic Brain Injuries, Ischemic Stroke, Hemorrhagic Stroke, Intracerebral, Meningitis/Encephalitis, Status Epilepticus
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Atezolizumab, Niraparib, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide; Biological · Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Effect of Repetitive Transcranial Direct Current Stimulation (tDCS) on Chronic Pelvic Pain

Effect of Bracing Versus No Bracing in Stable Thoracolumbar Compression and Burst Fractures

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3

Chest Dysphoria in Transmasculine Spectrum Adolescents

ENA-001 for Opioid Induced Respiratory Depression

Healthcare Worker Resilience as Measured by Physiologic Feedback

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Pharmacokinetic Alterations During ECMO

Trauma-focused Psychodynamic Psychotherapy for LGBT Patients With Post-traumatic Stress Disorder

A Prospective Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AC

VR-based EF Rehabilitation for Pediatric TBI

A Clinical Decision Support Tool for Electronic Health Records

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Testing of a New Therapeutic Vibration Device to Reduce Neuromuscular Weakness in Hospitalized Patients

QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol

FR901228 in Treating Patients With Recurrent High-Grade Gliomas

A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)

Reducing Cardiometabolic Risk and Promoting Functional Health in Older Adults With Obesity and Prediabetes

Boosting Primary Care Awareness and Treatment of Childhood Hypertension

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Does Manual Therapy Provide Immediate Improvement in Lumbar Range of Motion?

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Recovery Trajectory for Coma and Disorders of Consciousness

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy